Evidence map›Paper›PMID 31661796›Full record

ReviewInternational journal of molecular sciences2019

Multivalent Carbonic Anhydrases Inhibitors.

Fabrizio Carta, Pascal Dumy, Claudiu T Supuran, Jean-Yves Winum

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Carbonic Anhydrases: A Superfamily of Ubiquitous Enzymes.International journal of molecular sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Fabrizio CartaDepartment of Neurofarba, University of Florence, 50019 Sesto Fiorentino, Italy. fabrizio.carta@unifi.it.ORCID 0000-0002-1141-6146
Pascal DumyInstitut des Biomolécules Max Mousseron (IBMM), École nationale supérieure de chimie de Montpellier (ENSCM), Université de Montpellier, CEDEX 05, 34296 Montpellier, France. pascal.dumy@enscm.fr.
Claudiu T SupuranDepartment of Neurofarba, University of Florence, 50019 Sesto Fiorentino, Italy. claudiu.supuran@unifi.it.ORCID 0000-0003-4262-0323
Jean-Yves WinumInstitut des Biomolécules Max Mousseron (IBMM), École nationale supérieure de chimie de Montpellier (ENSCM), Université de Montpellier, CEDEX 05, 34296 Montpellier, France. jean-yves.winum@umontpellier.fr.ORCID 0000-0003-3197-3414
École Nationale Supérieure de Chimie de Montpellier · FRUniversity of Florence · IT

Funding

Agence Nationale de la Recherche ANR-10- LABX-05-01Ligue Contre le Cancer Comité des Pyrénées Orientales
6 · The paper itself

Abstract

Biomolecular recognition using a multivalent strategy has been successfully applied, this last decade on several biological targets, especially carbohydrate-processing enzymes, proteases, and phosphorylases. This strategy is based on the fact that multivalent interactions of several inhibitory binding units grafted on a presentation platform may enhance the binding affinity and selectivity. The zinc metalloenzymes carbonic anhydrases (CAs, EC 4.2.1.1) are considered as drug targets for several pathologies, and different inhibitors found clinical applications as diuretics, antiglaucoma agents, anticonvulsants, and anticancer agents/diagnostic tools. Their main drawback is related to the lack of isoform selectivity leading to serious side effects for all pathologies in which they are employed. Thus, the multivalent approach may open new opportunities in the drug design of innovative isoform-selective carbonic anhydrase inhibitors with biomedical applications.

Indexed as

Carbonic Anhydrase InhibitorsCarbonic AnhydrasesDendrimersDrug DesignGoldHumansIsoenzymesNanoparticlesNanotubesPolyaminesZincCarbonic Anhydrase InhibitorsCarbonic AnhydrasesDendrimersGoldIsoenzymesPoly(amidoamine)PolyaminesZincCA isoformscarbonic anhydrasesinhibitorsmultifunctionnal scaffoldmultivalencymultivalent

Identifiers

PMID31661796
PMCPMC6862271
OpenAlexW2981540373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.